Elysian supports Mergon's acquisition of Inmo-Tech, strengthening its healthcare manufacturing capabilities in Ireland

Elysian Capital is delighted to announce that Mergon Group has completed the acquisition of Inmo-Tech Limited, a specialist manufacturer of precision injection moulded components for the healthcare and medical device sectors, based in Enniscrone, Co. Sligo.

Mergon, an engineering-led, global manufacturing group with operations in Ireland, USA, the Czech Republic, the UK and Mexico, and trusted by healthcare leaders including Abbott, Beckman and Pfizer, has acquired Inmo-Tech to strengthen its healthcare capabilities and support its long-term growth ambitions in the sector.

Inmo-Tech brings complementary injection moulding expertise, an established manufacturing facility and a highly experienced team. As part of Mergon Group, Inmo-Tech will be able to draw on the Group’s wider engineering, automation, product development, project management and global manufacturing capabilities.

Commenting on the acquisition, Stéphane Maravel, CEO of Mergon Group, said: “We are delighted to welcome Inmo-Tech and its employees to Mergon Group. Inmo-Tech has built a strong reputation for specialist injection moulding in healthcare, supported by deep technical knowledge and a committed team. The business is an excellent strategic fit for Mergon. Together, we can build on its existing strengths, support its customers and create new growth opportunities.”

James Cunningham, partner at Elysian, said "We are pleased to support the acquisition of Inmo-Tech which is the second bolt on since we invested in Mergon. The first, Mergon UK, demonstrated management's ability to extend the geographic reach of the business while Inmo-Tech shows the opportunities to build out in a sector."